MCID: MXD026
MIFTS: 45

Mixed Glioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Mixed Glioma

MalaCards integrated aliases for Mixed Glioma:

Name: Mixed Glioma 12 54 15
Mixed Gliomas 12 71
Mixed Neuroglial Tumor 12
Glioma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5076
MeSH 43 D005910
NCIt 49 C3903
SNOMED-CT 67 22217002
UMLS 71 C0017638 C0259783

Summaries for Mixed Glioma

MalaCards based summary : Mixed Glioma, also known as mixed gliomas, is related to oligoastrocytoma and mixed oligodendroglioma-astrocytoma. An important gene associated with Mixed Glioma is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Glioma and MicroRNAs in cancer. The drugs Midazolam and Trametinib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and testes, and related phenotypes are Decreased sensitivity to paclitaxel and growth/size/body region

Related Diseases for Mixed Glioma

Diseases related to Mixed Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 33.1 MGMT IDH2 GFAP
2 mixed oligodendroglioma-astrocytoma 32.9 PTEN MGMT
3 glial tumor 30.9 PTEN OLIG2 IDH1
4 anaplastic oligodendroglioma 30.4 OLIG2 MGMT IDH2
5 neuroma 29.8 NF1 MGMT GFAP
6 glioma 29.3 TP53 PTEN PDGFRA NF1 IDH2 IDH1
7 malignant glioma 29.3 TP53 PTEN MGMT GFAP EGFR
8 rhabdomyosarcoma 28.6 TP53 PTEN PDGFRA NES EGFR
9 gliomatosis cerebri 28.4 TP53 PTEN NES IDH1 GFAP EGFR
10 benign ependymoma 28.3 PDGFRA NF1 NES MGMT GFAP EGFR
11 oligodendroglioma 27.6 TP53 PTEN PDGFRA OLIG2 NF1 MGMT
12 glioma susceptibility 1 27.2 TP53 PTEN PDGFRA OLIG2 NES MGMT
13 juvenile pilocytic astrocytoma 27.2 PTEN OLIG2 NF1 NES MGMT KIAA1549
14 glioblastoma multiforme 26.9 TP53 PTEN PDGFRA NF1 NES MGMT
15 adult brainstem mixed glioma 12.4
16 anaplastic oligoastrocytoma 11.6
17 extraventricular neurocytoma 10.6 IDH1 GFAP
18 deep leiomyoma 10.5 PDGFRA GFAP
19 enchondroma 10.5 IDH2 IDH1
20 third ventricle chordoid glioma 10.5 OLIG2 GFAP
21 cytogenetically normal acute myeloid leukemia 10.5 IDH2 IDH1
22 intracranial chondrosarcoma 10.5 IDH2 IDH1
23 periosteal chondrosarcoma 10.5 IDH2 IDH1
24 angiocentric glioma 10.5 IDH1 GFAP
25 urethra transitional cell carcinoma 10.4 TP53 GFAP
26 juxtacortical chondroma 10.4 IDH2 IDH1
27 undifferentiated pleomorphic sarcoma 10.4 PDGFRA IDH2 IDH1
28 tanycytic ependymoma 10.4 OLIG2 IDH1 GFAP
29 adult brain stem glioma 10.4 MGMT IDH2 IDH1
30 central nervous system rhabdomyosarcoma 10.4 MGMT IDH2 IDH1
31 esophageal basaloid squamous cell carcinoma 10.3 TP53 EGFR
32 esophagus verrucous carcinoma 10.3 TP53 EGFR
33 interval angle-closure glaucoma 10.3 IDH2 IDH1
34 systemic mastocytosis 10.3 PDGFRA IDH2 IDH1
35 enchondromatosis, multiple, ollier type 10.3 IDH2 IDH1 ATRX
36 breast hemangioma 10.3 TP53 IDH2 IDH1
37 intraductal breast neoplasm 10.3 TP53 IDH2 IDH1
38 pituitary carcinoma 10.3 TP53 MGMT GFAP
39 high-grade astrocytoma 10.3 PTEN IDH1
40 clear cell chondrosarcoma 10.3 IDH2 IDH1
41 chordoid glioma 10.3 TP53 GFAP FUBP1
42 cervical adenosquamous carcinoma 10.3 PDGFRA EGFR
43 small intestine leiomyoma 10.3 PDGFRA NF1
44 soft tissue sarcoma 10.3 TP53 EGFR
45 choroid plexus cancer 10.3 TP53 GFAP ATRX
46 breast malignant phyllodes tumor 10.3 TP53 EGFR
47 breast duct papilloma 10.2 PTEN IDH2 IDH1
48 atypical teratoid rhabdoid tumor 10.2 TP53 GFAP ATRX
49 anaplastic ependymoma 10.2 PTEN GFAP
50 childhood medulloblastoma 10.2 TP53 PDGFRA EGFR

Graphical network of the top 20 diseases related to Mixed Glioma:



Diseases related to Mixed Glioma

Symptoms & Phenotypes for Mixed Glioma

GenomeRNAi Phenotypes related to Mixed Glioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.62 NF1 PTEN

MGI Mouse Phenotypes related to Mixed Glioma:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.2 ATRX EGFR FUBP1 GFAP IDH1 NF1
2 cardiovascular system MP:0005385 10.19 ATRX EGFR FUBP1 GFAP IDH2 NF1
3 mortality/aging MP:0010768 10.18 ATRX EGFR FUBP1 GFAP IDH1 MGMT
4 embryo MP:0005380 10.08 ATRX EGFR FUBP1 NF1 PDGFRA PTEN
5 muscle MP:0005369 9.97 EGFR GFAP NF1 OLIG2 PDGFRA PTEN
6 nervous system MP:0003631 9.96 ATRX EGFR FUBP1 GFAP MGMT NF1
7 neoplasm MP:0002006 9.92 EGFR IDH2 MGMT NF1 OLIG2 PDGFRA
8 limbs/digits/tail MP:0005371 9.91 EGFR IDH2 NF1 PDGFRA PTEN TP53
9 respiratory system MP:0005388 9.61 EGFR FUBP1 IDH1 MGMT NF1 OLIG2
10 pigmentation MP:0001186 9.55 EGFR NF1 PDGFRA PTEN TP53
11 vision/eye MP:0005391 9.23 ATRX EGFR FUBP1 GFAP NF1 OLIG2

Drugs & Therapeutics for Mixed Glioma

Drugs for Mixed Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 568)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Trametinib Approved Phase 4 871700-17-3 11707110
3
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
4
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
5 Anti-Anxiety Agents Phase 4
6 Excitatory Amino Acid Antagonists Phase 4
7 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Phase 4
8
Lenograstim Approved, Investigational Phase 3 135968-09-1
9
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
10
Dextroamphetamine Approved, Illicit Phase 3 51-64-9 5826
11
Donepezil Approved Phase 3 120014-06-4 3152
12
Dalteparin Approved Phase 3 9005-49-6
13
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
14
Somatostatin Approved, Investigational Phase 2, Phase 3 51110-01-1, 38916-34-6 53481605
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Thioguanine Approved Phase 3 154-42-7 2723601
17
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
18
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
19
Ethanol Approved Phase 2, Phase 3 64-17-5 702
20
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
21
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
22
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
23
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
24
Etoposide Approved Phase 3 33419-42-0 36462
25
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
26
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
27
leucovorin Approved Phase 3 58-05-9 6006 143
28
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
29
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
30
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
31
Histamine Approved, Investigational Phase 3 51-45-6 774
32
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
33
Cyproheptadine Approved Phase 3 129-03-3 2913
34
Norepinephrine Approved Phase 3 51-41-2 439260
35
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
36
Ornithine Approved, Nutraceutical Phase 3 3184-13-2, 70-26-8 6262
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
38 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
39 Dianhydrogalactitol Investigational Phase 3 23261-20-3
40 Analgesics, Non-Narcotic Phase 3
41 Anti-Inflammatory Agents, Non-Steroidal Phase 3
42 Emetics Phase 3
43 Antiparasitic Agents Phase 3
44 Antiprotozoal Agents Phase 3
45 Anesthetics, Inhalation Phase 3
46 Cholinesterase Inhibitors Phase 3
47 Heparin, Low-Molecular-Weight Phase 3
48 calcium heparin Phase 3
49 Endothelial Growth Factors Phase 2, Phase 3
50 Antimalarials Phase 3

Interventional clinical trials:

(show top 50) (show all 1393)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
2 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
3 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
4 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
5 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Not yet recruiting NCT03975829 Phase 4 dabrafenib;trametinib
6 A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
7 Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study Unknown status NCT00256425 Phase 3
8 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
9 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
10 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
11 A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
12 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
13 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
14 A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
15 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
16 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
17 A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
18 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
19 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
20 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
21 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
22 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
23 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
24 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
25 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
26 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
27 PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
28 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
29 A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) Completed NCT00135876 Phase 3 dalteparin
30 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
31 Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV) Completed NCT01167322 Phase 3 NPC-07 for oral administration
32 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
33 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
34 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
35 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
36 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
37 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
38 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
39 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
40 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
41 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
42 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
43 A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Completed NCT00561990 Phase 2, Phase 3 Nimotuzumab
44 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
45 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
46 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
47 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Recruiting NCT04164901 Phase 3 AG-881;Matching Placebo
48 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
49 A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
50 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide

Search NIH Clinical Center for Mixed Glioma

Genetic Tests for Mixed Glioma

Anatomical Context for Mixed Glioma

MalaCards organs/tissues related to Mixed Glioma:

40
Brain, T Cells, Testes, Spinal Cord, Breast, Endothelial, Bone

Publications for Mixed Glioma

Articles related to Mixed Glioma:

(show top 50) (show all 301)
# Title Authors PMID Year
1
A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas. 61 54
15635072 2005
2
Tissue culture of human neurocytomas induces the expression of glial fibrilary acidic protein. 61 54
10451427 1998
3
Semiquantitative postembedding characterization of intermediate filaments in central nervous system lesions using immunoelectron microscopy. 61 54
9044656 1995
4
Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. 61
31832215 2019
5
Synchronous identification of a dysembryoplastic neuroepithelial tumor (DNET) and an oligodendroglioma in a patient: A case report. 61
31262396 2019
6
Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. 61
31136584 2019
7
Concurrent Versus Sequential Chemoradiation for Low-grade Gliomas Meeting RTOG 9802 Criteria. 61
30768441 2019
8
Glioblastoma in the setting of prior lower grade gliomas - insights from SEER database. 61
30279958 2018
9
Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach. 61
28958143 2018
10
[Adult intramedullary gliomas]. 61
28527519 2017
11
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy. 61
27271289 2017
12
Clinicopathological features and microsurgical outcomes for giant pediatric intracranial tumor in 60 consecutive cases. 61
28180935 2017
13
The inhibiting activity of meadowsweet extract on neurocarcinogenesis induced transplacentally in rats by ethylnitrosourea. 61
27838807 2017
14
Proceedings of the 2016 National Toxicology Program Satellite Symposium. 61
27821709 2017
15
Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. 61
28248126 2016
16
Unique case of oligoastrocytoma with recurrence and grade progression: Exhibiting differential expression of high mobility group-A1 and human telomerase reverse transcriptase. 61
27672647 2016
17
Morphological Patterns of Intracranial Lesions in a Tertiary Care Hospital in North Karnataka: A Clinicopathological and Immunohistochemical Study. 61
27656442 2016
18
Nogo-A inhibits the migration and invasion of human malignant glioma U87MG cells. 61
27109183 2016
19
Primary Spinal Oligoastrocytoma. 61
27092919 2016
20
Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. 61
26115961 2016
21
The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. 61
26530262 2015
22
Updates in Molecular Pathology of Central Nervous System Gliomas in Adults. 61
26517249 2015
23
Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"? 61
25359109 2015
24
Treatment of anaplastic glioma. 61
25468227 2015
25
[Low-grade gliomas in adults]. 61
25391745 2014
26
Mixed Glioma (Oligoastrocytoma) in the brain of an African Hedgehog (Atelerix albiventris). 61
25172052 2014
27
Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors. 61
25007776 2014
28
Immunohistochemical evaluation of tissue factor, fibrin/fibrinogen and D-dimers in canine gliomas. 61
24745770 2014
29
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. 61
23644658 2014
30
Trends in childhood brain tumor incidence, 1973-2009. 61
23925828 2013
31
Analyzing agreement patterns of intraoperative central nervous system lesion reporting according to type and grade. 61
24130410 2013
32
The Evangelismos hospital central nervous system tumor registry: Analysis of 1414 cases (1998-2009). 61
23533006 2013
33
Immunohistochemical characterization of spontaneous and acrylonitrile-induced brain tumors in the rat. 61
22821367 2013
34
GFAP-positive neoplastic astrocytes in spontaneous oligodendrogliomas and mixed gliomas of rats. 61
23076037 2013
35
Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. 61
22890969 2012
36
Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event. 61
22844452 2012
37
Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. 61
21889777 2011
38
The effect of WHO reclassification of necrotic anaplastic oligoastrocytomas on incidence and survival in glioblastoma. 61
21229290 2011
39
Glioma Indian scenario: Is there a human leucocyte antigen association? 61
22346237 2011
40
Pleomorphic xanthoastrocytoma and oligodendroglioma: collision of 2 morphologically and genetically distinct anaplastic components. 61
21214337 2011
41
Risk factors for oligodendroglial tumors: a pooled international study. 61
21149253 2011
42
Primary and metastatic intraaxial brain tumors: prospective comparison of multivoxel 2D chemical-shift imaging (CSI) proton MR spectroscopy, perfusion MRI, and histopathological findings in a group of 159 patients. 61
21165751 2011
43
[Beneficial outcomes of an interdisciplinary psychoeducative group intervention for patients with malignant gliomas and their relatives]. 61
21312092 2011
44
Coexistent pathology in chronic epilepsy patients with neoplasms. 61
20495542 2010
45
Persistent outpatient hyperglycemia is independently associated with survival, recurrence and malignant degeneration following surgery for hemispheric low grade gliomas. 61
19589201 2010
46
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital. 61
21299082 2010
47
Central nervous system. 61
22112477 2010
48
Tumours arising in the setting of paediatric chronic epilepsy. 61
20632818 2010
49
A retrospective study of primary brain tumors in children under 14 years of age at PIMS, Islamabad. 61
21198267 2010
50
Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. 61
19361270 2010

Variations for Mixed Glioma

Expression for Mixed Glioma

Search GEO for disease gene expression data for Mixed Glioma.

Pathways for Mixed Glioma

GO Terms for Mixed Glioma

Cellular components related to Mixed Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 8.8 TP53 PTEN ATRX

Biological processes related to Mixed Glioma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.7 TP53 PTEN MGMT
2 2-oxoglutarate metabolic process GO:0006103 9.51 IDH2 IDH1
3 DNA damage response, signal transduction by p53 class mediator GO:0030330 9.49 TP53 ATRX
4 regulation of synaptic transmission, GABAergic GO:0032228 9.48 PTEN NF1
5 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.46 TP53 EGFR
6 response to organic cyclic compound GO:0014070 9.46 PTEN MGMT IDH1 EGFR
7 NADP metabolic process GO:0006739 9.43 IDH2 IDH1
8 cellular response to reactive oxygen species GO:0034614 9.43 TP53 PDGFRA EGFR
9 forebrain morphogenesis GO:0048853 9.4 PTEN NF1
10 negative regulation of neuroblast proliferation GO:0007406 9.37 TP53 NF1
11 isocitrate metabolic process GO:0006102 9.32 IDH2 IDH1
12 glyoxylate cycle GO:0006097 8.96 IDH2 IDH1
13 wound healing GO:0042060 8.92 TP53 PDGFRA NF1 EGFR

Molecular functions related to Mixed Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet-derived growth factor receptor binding GO:0005161 9.16 PTEN PDGFRA
2 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
3 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Mixed Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....